Objective: The role of biochemical and functional markers of microvascular dysfunction to predict cardiovascular outcomes in nondialyzed chronic kidney disease (CKD) remains unclear. In this prospective cohort study, we assessed whether biochemical [serum level of angiopoietin-2 (Ang-2), asymmetric and symmetric dimethylarginin] and functional (laser Doppler flowmetry) measures of microvascular function predicted cardiovascular events, cardiovascular and all-cause mortality in CKD patients.
INTRODUCTION
C ardiovascular disease is the major cause of morbidity and mortality in patients with chronic kidney disease (CKD) [1] . Furthermore, cardiovascular mortality in CKD patients is even more frequent than progression of renal failure to end-stage renal disease (ESRD) [2] . The development of cardiovascular disease in CKD patients involves the complex processes of progressive atherosclerosis and arteriosclerosis that includes microvascular dysfunction [3] .
Following the discovery of the pivotal role of nitric oxide (NO) in endothelium-derived vascular relaxation by Furchgott and Zawadzki [4] , different methods have been developed and used in laboratories for the early diagnosis of subclinical atherosclerosis and microvascular dysfunction. Only a few of these, however, such as the detection of minute amounts of albuminuria, increased high-sensitivity C-reactive protein levels or the measurement of carotid intima-media thickness have gained a role in everyday practice [5] . Laser Doppler flowmetry (LDF) allows the noninvasive assessment of skin microvascular reactivity. Different tests have been developed for the evaluation of microcirculation with LDF. Using LDF with iontophoresis of acetylcholine and sodium nitroprusside or with the postocclusive reactive hyperemia test (PORH) of the capillaries of the forearm, we previously demonstrated endothelial dysfunction in patients with hypertension [6] and patients on dialysis [7] .
Endothelial dysfunction could be estimated by different serum molecules that could also be linked to cardiovascular events in CKD, such as angiopoietin-2 (Ang-2), asymmetric dimethylarginin (ADMA) or symmetric dimethylarginin (SDMA) [8] [9] [10] . Ang-2 functions as a dynamic autocrine negative regulator of the quiescent endothelium through inhibiting the endothelial receptor tyrosine kinase Tie-2-regulated signal transduction pathways [11] . Previously, we found that Ang-2 increases with advanced CKD [12] and in a combined cohort of CKD patients stage 4 and 5, it was a predictor of mortality [8] . However, its predictive value for cardiovascular outcome on nondialyzed CKD patients has never been tested.
ADMA and its isomer SDMA are endogenous products of methylated protein turnover that are present in the circulation in micromolar levels [13] . ADMA directly inhibits NO synthesis by competitively binding nitrogen-monoxide synthases (NOS), and both ADMA and SDMA may also reduce NO production by inhibiting the cellular uptake of L-arginine, a precursor of NO [13] . Both these molecules are potential biomarkers of cardiovascular outcome in CKD, but their importance has not been conclusively clarified yet.
When a biological measure applies to be a marker of cardiovascular risk, among others, follow-up studies are also required to demonstrate its predictive value for different outcomes before their introduction into clinical practice [14] . Although many groups used LDF to evaluate endothelial dysfunction, only one work is available in ESRD patients about its predictive value for cardiovascular mortality [15] and none in nondialyzed CKD. Furthermore, neither the correlation, nor the predictive superiority of biomarkers vs. LDF to depict endothelial dysfunction and cardiovascular events, has been shown in nondialyzed CKD patients.
Therefore, the aim of our study was to evaluate whether traditional risk factors, LDF parameters of iontophoresis and PORH were related to markers of microvascular dysfunction, such as Ang-2, ADMA and SDMA in stage 1-5 CKD nondialyzed patients. We also aimed to study the prognostic importance of these parameters in our patients for cardiovascular events and cardiovascular or all-cause mortality. We hypothesized that the functional and biochemical markers of microvascular dysfunction would be associated with each other and that they would be predictors of cardiovascular events.
MATERIALS AND METHODS
This was a prospective cohort study of hypertensive CKD patients with baseline cross-sectional analysis between the LDF parameters and biochemical markers of microvascular function, and analysis of these microvascular markers as predictors for cardiovascular events, cardiovascular -and all-cause mortality during follow-up. Initially 108 patients were enrolled but finally only 105 patients were followed up and analyzed as three patients could not be contacted after the initial measurements.
Convenience sampling was used with consecutive inclusion of CKD patients presenting at two tertiary care nephrology outpatient clinics who were invited to participate in the study. None of the patients were hospitalized at the time of baseline investigations. No other specific exclusion criteria were applied. Antihypertensive treatment was tailored according to the latest recommendations of the European Society of Hypertension [16] . CKD patients in stage 1-5, nondialyzed, who gave written informed consent for participation, were included and two appointments within the next 2 weeks for blood sampling and LDF measurements were arranged, Then patients were followed for a median of 66.6 months (interquartile range: 39.8-80.4). Follow-up data were collected between April 2007 and July 2014 by telephone interviews with the patients, their general practitioners or treating physicians, and the information gathered were in all cases verified by chart review. Follow-up was censored at the last occurrence of a documented cardiovascular event (acute coronary syndrome, heart failure requiring hospitalization, stroke or transient ischemic attack, peripheral artery disease verified by angiography or need for an intervention) or death due to the above cardiovascular events or any other causes. Laboratory data and vascular biomarkers were not collected during the follow-up.
The protocol was approved by the Ethics Committees of the two hospitals that the outpatient clinics belonged to and was carried out in accordance with the tenets of the Declaration of Helsinki.
Epidemiologic and laboratory data
Baseline data on smoking habits (current), diabetes (any type), hypertension, coronary artery disease (previous acute myocardial infarction or coronary intervention), chronic heart failure (previous diagnosis), peripheral artery disease (documented by angiography or intervention) and cerebrovascular disease (previous stroke or transient ischemic attack) were collected by health record review. Framingham 10-year cardiovascular risk scores were calculated for sensitivity analysis of the results [17] .
Blood samples were taken after overnight fasting, between 0700 and 0800 h. In that morning, regular medications were not taken, but there has been no medication withdrawal on previous days. Serum levels of hemoglobin, potassium, calcium, phosphorus, albumin, creatinine, C-reactive protein (CRP), cholesterol were evaluated at baseline by a Hitachi auto-analyzer. Intact parathormone 1-84 was determined by an immune-chemiluminometric two-site assay (CIBA-CORNING, Frenwald, Germany). Baseline estimated glomerular filtration ratio (eGFR) was calculated using the four-variable Chronic Kidney Disease Epidemiology Collaboration equation. Albuminuria was characterized by albumin-to-creatinine ratio measured from first morning spot urine sample. Circulating serum Ang-2 concentrations were measured by an in-house immunoluminometric assay as previously reported by our group in detail [18] . The coefficient of variation was less than 6%. The sensitivity threshold was 0.2 ng/ml. Assays were performed in duplicate by a single investigator blinded to patients' characteristics and outcome. Plasma ADMA and SDMA levels were assessed using HPLC-tandem mass spectrometry [19] .
Laser Doppler flowmetry measurements
LDF measurements were performed at the second appointment between 10 and 12 a.m. Patients had a nonstandardized light breakfast and took their regular medications 3 h before the LDF measurements. Patients were asked to refrain from smoking on the day of the study and not to consume caffeine-containing drinks at least 4 h before the start of the measurements. LDF measurements and blood sampling were performed on separate days within a week.
LDF measurements were carried out in a temperaturecontrolled room (24 AE 1 8C). Upon arrival and a 5-min rest, two consecutive brachial blood pressure measurements were taken 1 min apart on each arm in the sitting position with a validated BpTru device (VSM Medtech, Vancouver, Canada). The mean value was calculated for each arm, and the higher of these was further taken as brachial SBP and DBPs and heart rate. Then patients were set in the supine position for a 20-min acclimatization period. Before starting the LDF measurements, the flexor surface of the right forearm was gently cleansed using alcohol solution.
The laser Doppler instrument Periflux 5001 (wavelength 780 mm) and the micropharmacology system PeriIont were used during the study. The same iontophoresis protocols were used as in our previous studies [6, 7] . The drug delivery electrode was filled with 140-ml acetylcholine 1% (Clinalfa AG, Läufelfingen, Switzerland) and was attached with the laser probe to the volar surface of the right forearm. The position of the probe was chosen to avoid hair, freckles and broken skin. The dispersive electrode was attached to the volar aspect of the wrist to complete the circuit. We placed a control standard probe 4 cm laterally from the drug delivery electrode. After registration of the baseline flow (60 s), two doses of acetylcholine were delivered using an anodal current (0.1 mA for 30 s and 0.16 mA for 30 s) with a 120-s interval. Using a new delivery electrode, two doses of sodium nitroprusside 1% (Nitropress; Abbott, Lake Bluff, Illinois, USA) were delivered using a catodal current (0.1 mA for 20 s and 0.1 mA for 30 s) with a 120-s interval.
During the PORH test after the registration of the baseline flow (60 s), arterial occlusion was performed with a suprasystolic pressure using the pneumatic cuff of a sphygmomanometer for 3 min (biological zero); then after the release of the pressure, we measured the skin hyperemia on the volar surface of the left forearm 10 cm below the elbow with a standard laser Doppler probe. Another standard probe was put on the skin of the right forearm as a control.
About the principles of LDF measurements, we also refer to our previous publications [6, 7] . The LDF output is semiquantitative and is expressed in perfusion units (PU) of output voltage (1 PU ¼ 10 mV) in accordance with the general consensus (European Laser Doppler Users Groups, London 1992). As the output is not easily translated into absolute values of blood flow, in the case of iontophoresis, the magnitude of the change in skin perfusion after the second administered dose of acetylcholine (ACh) or sodium nitroprusside (SNP) was calculated as the ratio between peak and baseline perfusion and expressed as percentage of baseline. In the case of PORH, the software analyzed the data automatically and calculated several indexes such as the initial baseline value, slope value, peak flow, percentage change in perfusion from baseline to maximum values, time to reach the maximum hyperemia, time to reach the half value after the maximum hyperemia and the area of hyperemia. This latter measure (abbreviated as PORH HA , unit: PU s -perfusion unit second) seems to be the most accurate parameter to assess the hyperemic response, as it includes three variables (speed, intensity and duration), and this was used in the analyses as representative of the microvascular function of PORH [20, 21] .
According to previous measurements in our laboratory [6] , the day-to-day variability of this system was 16-21%, which is comparable with other studies [21] and to the wildly accepted brachial artery flow-mediated vasodilation technique (17.5%) [22] . The LDF measurements were performed and analyzed by the same examiners (J.N., J.E., G.G. and L.S.) throughout the study.
Statistical analysis
All data analysis was performed by STATA IC version 10.0 (StataCorp Lp., College Station, Texas, USA) and Statistica version 11.0 (StatSoft Inc., Tulsa, Oklahoma, USA). Continuous data are given as mean and standard deviation, or in the case of evidence against normal distribution, as median and interquartile range. For further analyses, nonnormally distributed data were transformed logarithmically. All those variables that were log-transformed had positively skewed distribution that improved after the transformation visually although not all satisfied tests for normality. Thus in the statistical modeling described in the next paragraphs, logtransformed and nonlog transformed variables were included in the models simultaneously. In the group comparisons of anthropometric and clinical parameters, Student's t test for independent samples, Mann-Whitney U tests and chi-squared tests were used, as appropriate.
In the baseline cross-sectional analyses, first Spearman correlations were run between the six microvascular parameters (ACh, SNP, PORH HA , Ang-2, ADMA and SDMA). Then, univariate and multivariate linear regressions were performed to determine associations of these six microvascular parameters with baseline clinical variables and used medications. The predictor clinical variables considered were those listed in Table 1 . The variables that showed a significant association with the given microvascular variable in univariate models were considered in the final multivariate model.
The primary outcome of the study was the occurrence of the combined endpoint of cardiovascular events and cardiovascular mortality or cardiovascular events and all-cause mortality, as defined above.
To assess the predictive values of ACh, SNP, PORH HA , Ang-2, ADMA and SDMA for the primary outcome multiple failure times, Cox proportional hazard regression analyses were used with conditional risk set modeling. This method accommodates for the fact that one patient may have had more than one event during follow-up. We first performed univariate analyses considering variables listed in Table 1 and all groups of medications. Confounding was addressed in multivariate Cox-regression models with adjustment for potential clinical predictors. In the case of medications, those groups were considered that were independently related to the three LDF or three biochemical parameters listed in Table 3 or those that showed a univariate association with the outcomes (P < 0.1). In the final multivariate models instead of the use of separate variables for 'oral antidiabetic drugs' and 'insulin', the variable 'diabetes' was used, as these two groups did not improve the Cox-models. Final models were selected using backward elimination to reach the most parsimonious models. As a sensitivity analysis, we repeated these analyses using the other endpoint (cardiovascular events and all-cause mortality) as the outcome. For further sensitivity analysis area under the receiver-operator characteristics curves were compared, and net reclassification improvement (NRI) was calculated from the probability scores of logistic regression models using the Framingham cardiovascular risk score and lnPORH HA as predictors and both primary outcomes as dependent variables [23] .
A P value with a two-sided alpha of less than 0.05 was considered statistically significant. Hazard ratios are presented with their corresponding 95% confidence intervals.
RESULTS
We report data on 105 patients with CKD at the two centers who had follow-up data. Baseline clinical, laboratory, hemodynamic and LDF data of the patients are presented in Table 1 , comparing those with an eGFR less than or equal to those with higher than the median 35 ml/min per 1.73 m 2 . Diabetic (27.6%) and hypertensive nephropathy (18.1%), tubulointerstitial disease (18.1%) and glomerulonephritis (14.1%) were the most frequent causes of CKD. Almost all patients took an angiotensin-converting enzyme (ACE)-inhibitor or angiotensin receptor blocker (88.6%), many of them a diuretic (74.3%), calcium channel blocker (53.3%) or beta-blocker (54.2%), less alpha-blocker (18.1%) and centrally effective antihypertensive drugs (13.3%). Sixty-two percent of the patients were on statins, 22.8% on oral antidiabetics, 21% on insulin, 14.3% on nitrate and 12.4% on fibrate therapy. Half of the patients took any kind of antiplatelet therapy. The group with an eGFR below 35 ml/ min per1.73 m 2 had a worse metabolic status as indicated by their elevated phosphorus, parathyroid hormone, CRP, urinary albumin-to-creatinine ratio and lower hemoglobin values. No significant differences were found between these two groups in respect of their ACh, SNP or PORH HA values. Ang-2, ADMA and SDMA levels, however, were significantly higher in those with more advanced CKD. Table 2 presents Spearman correlation coefficients between different LDF and serum microvascular biomarkers. There were significant baseline correlations among the three biochemical parameters and also among the three LDF parameters, but not between the biochemical and LDF measures. Table 3 shows independent associations of the six vascular parameters with other measures at baseline, based on multivariate linear regression analysis. The highest R 2 was found for lnSDMA mainly due to its strong relation to eGFR. Overall however, the model R 2 values for the six parameters were small or moderate.
Outcome status was available for all the 105 patients at the end of the follow-up. By that time, a total of 50 primary outcome events occurred in 38 patients. It represents an incidence rate of cardiovascular diseases of 8.5 events per 100 patient-years in our population. Sixteen patients died of cardiovascular causes (acute coronary syndrome n ¼ 4, stroke n ¼ 3, heart failure n ¼ 8, and peripheral artery disease n ¼ 1), and there were 34 additional cardiovascular events (acute coronary syndrome n ¼ 8, stroke n ¼ 6, heart failure n ¼ 13, peripheral artery disease n ¼ 7). During follow-up, 12 patients died of non-cardiovascular causes (senile dementia n ¼ 5, pneumonia n ¼ 2, accidents n ¼ 2, lung cancer n ¼ 1, colorectal cancer n ¼ 1, pancreatitis n ¼ 1). Table 4 summarizes the results of the univariate and multivariate Cox proportional hazard regression analyses for all microvascular LDF and biochemical parameters and for those other baseline variables that showed a significant association with the endpoints. In univariate models, only lnPORH HA and lnAng-2, but not the other four baseline microvascular parameters, were significantly related to these two outcomes. In multivariate analyses, lnPORH HA remained an independent predictor of cardiovascular mortality and cardiovascular events besides age, CRP and diabetes. Although LnAng-2 was a significant predictor of this outcome (cardiovascular mortality and cardiovascular events) independent of age, sex and baseline cardiovascular disease, but once diabetes or eGFR was introduced into the model it lost its statistical significance. When allcause mortality was introduced instead of cardiovascular mortality as outcome even lnPORH HA lost its predictive value leaving age, diabetes pulse pressure and the use of fibrates as independent risk factors.
Based on multivariate logistic regressions using the Framingham 10-year cardiovascular risk score and the Framingham score and lnPORH HA as predictors, both parameters were significantly related to cardiovascular events and cardiovascular mortality [1.07 (1.03-1.11) and 0.66 (0.43-1), respectively]. The Framingham risk score had an overall good discrimination [area under the curve (AUC), 0.75 standard error, 0.05]; however, the addition of lnPORH HA did not further improve discrimination (AUC, 0.76 standard error, 0.05, P ¼ 0.54). In contrast, the NRI showed a significant reclassification improvement of 21.8% (standard error, 0.09) using three risk categories (0-19.9, 20-44.9, !45%). However, only Framingham score but not lnPORH HA was an independent predictor of all-cause mortality and cardiovascular events [1.09 (1.04-1.14) and 0.75 (0.49-1.14), respectively].
DISCUSSION
The major finding of our cohort study is that among the tested functional (ACh, SNP, PORH HA ) and biochemical (Ang-2, ADMA, SDMA) microvascular parameters PORH HA independently predicted cardiovascular events and cardiovascular mortality in nondialyzed CKD patients. Nevertheless the robustness of traditional risk factors seems to outweigh the predictive role of this microvascular biomarker when all-cause mortality and incidence of cardiovascular events are considered.
The different LDF methods of iontophoresis have frequently been studied in pathological conditions. Acetylcholine is assumed to cause endothelial dependent, whereas sodium nitroprusside is endothelium-independent vasodilation [24] . Later studies however showed that the cutaneous blood flow increase induced by acetylcholine administration is also influenced by axon reflex and prostanoids as well [25] , suggesting that the acetylcholineinduced reactive hyperemia has also endothelium-independent components. When compared with our previous studies, the magnitude of the evoked hyperemia after acetylcholine and sodium nitroprusside iontophoresis in this work was between those who had only hypertension and those who were dialyzed, and lower compared with healthy controls [7] . Surprisingly however, no difference was found between those with less and more advanced CKD in their acetylcholine or sodium nitroprusside responses, and eGFR was not an independent determinant of these parameters. These findings are in agreement with a recent publication, in which Thang et al. [26] demonstrated that in patients with advanced CKD reactive hyperemia for acetylcholine and sodium nitroprusside iontophoresis were not associated with eGFR. At baseline, both acetylcholine and sodium nitroprusside responses were inversely related to the presence of diabetes. This is in line with the literature as Beer et al. [27] have previously shown that diabetes significantly influenced cutaneous vascular response to acetylcholine and sodium nitroprusside iontophoresis. Moreover, Brooks et al. [28] found a progressive fall of both acetylcholine and sodium nitroprusside-induced microvascular responsiveness in parallel with the development of microvascular complications of diabetes. The use of antiplatelet medication and diuretics were both independently and negatively associated with sodium nitroprusside-evoked hyperemia in our study. We suppose that these associations do not reflect a direct effect, but their use is a sign of the presence of more severe comorbidities, associated with lower overall microvascular reactivity.
From the different PORH parameters, we have chosen hyperemia area (PORH HA ), as it reflects speed, intensity and The variables considered in the multivariate linear regression models were age, sex, BMI, current smoking, diabetes, baseline cardiovascular disease, eGFR, lnCRP, hemoglobin, cholesterol, phosphorus, lnPTH, albumin, lnACR, SBP, brachial pulse pressure, heart rate, use of ACE-inhibitor or ARB, diuretics, beta-blockers, alpha-blockers, calcium channel blockers, centrally effective antihypertensive drugs, nitrate, statin, fibrate, oral antidiabetic drugs, insulin, antiplatelet drugs. ACh, maximum percentage laser Doppler flow increase in the forearm skin capillaries after acetylcholine iontophoresis; ACR, urinary albumin-to-creatinine ratio; ADMA, asymmetric dimethylarginin; CCB, calcium-channel blocker; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; ln, natural logarithm; PORH HA , postocclusive reactive hyperemia area; PTH, parathormone; RAASinh, ACE-inhibitors or ARBs; SDMA, symmetric dimethylarginin; SNP, maximum percentage laser Doppler flow increase in the forearm skin capillaries after sodium nitroprusside iontophoresis.
duration of the hyperemic response, and previously it was associated with the development of coronary heart disease in ESRD patients [15, 20] . We, however, found no significant difference in PORH HA between those with less and more advanced CKD, and eGFR was not an independent determinant of PORH HA . This, together with the results of iontophoresis, suggests that endothelial dysfunction evaluated by the different LDF tests is an early process, and that the progression of CKD per se does not influence its severity significantly, until dialysis becomes necessary. On the grander scheme of using PORH in CKD patients for the assessment and evaluation of cardiovascular risk, we think if other studies confirm our findings, PORH HA might be recommended for risk stratification in all stages of CKD. Hazard ratios represent a unit increase in the variable. ACh, maximum percentage laser Doppler flow increase in the forearm skin capillaries after acetylcholine iontophoresis; ACR, urinary albumin-to-creatinine ratio; ADMA, asymmetric dimethylarginin; Ang-2, angiopoietin-2; Antiplatelet, antiplatelet drugs; CCB, calcium channel blockers; Centrally eff, centrally effective antihypertensive drugs; CRP, C-reactive protein; CV, cardiovascular; eGFR, estimated glomerular filtration rate; ln, natural logarithm; Hb, hemoglobin; OAD, oral antidiabetic drugs; PORH AH , postocclusive reactive hyperemia area; PTH, parathormone; RAASinh, ACE-inhibitors and ARBs; SBP, peripheral SBP; SDMA, symmetric dimethylarginin; SNP, maximum percentage laser Doppler flow increase in the forearm skin capillaries after sodium nitroprusside iontophoresis. Bold and italic values demonstrate significance, when P < 0.05.
PORH HA , however, was inversely and significantly related to brachial pulse pressure that confirms the known link between microvascular and macrovascular function [29] . Stiff central arteries cause high pulsatility of central aortic pressure, resulting high transmission of pulsatile energy into the periphery, which is thought to promote microvascular injury [30] . PORH HA was also inversely associated with the use of calcium channel blockers and fibrates. As both of these groups of medications were found to be beneficial for vasodilatory responses measured with flow-mediated vasodilation [31] [32] [33] , we believe, these associations do not refer to a direct effect, rather the severity of comorbidities of patients.
There were significant baseline correlations among the three biochemical parameters of microvascular dysfunction and also among the three laser Doppler parameters, but not between the biochemical and laser Doppler measures. This finding suggests first that the measured parameters have their internal validity, and second that the biochemical parameters provide information on vessel function that is different from what laser Doppler functional tests provide.
Among the studied LDF parameters only PORH HA , but not ACh or SNP, was found to be a predictor of cardiovascular mortality and cardiovascular events. The predictive role of acetylcholine and sodium nitroprusside iontophoresis for cardiovascular events or mortality has not been studied previously [34] . Although our current data question the clinical use of iontophoresis for risk prediction in CKD, more confirmatory follow-up studies are needed in different populations before one may conclude that iontophoresis should be reserved for the laboratory use.
The predictive role of PORH HA in our patient population is in line with the findings of Kruger et al. [15] who demonstrated in ESRD patients that development of coronary artery disease was associated with the postocclusive recruitment of dermal capillaries. Although our data are the first to show an independent predictive value of PORH HA for cardiovascular mortality and cardiovascular events, even PORH HA lost its independent predictive role when all-cause mortality and cardiovascular events were considered as outcome. This is perhaps due to the robust effects of classical risk factors, such as age, diabetes or brachial pulse pressure, and also due to the difference in predictors of cardiovascular and all-cause mortality. The significant NRI means that PORH HA improved prediction of cardiovascular risk over the Framingham scores. It seems therefore that this simple LDF test is worth of further study and bears the promise of clinical application.
Significantly, in the final multivariate Cox-proportional regression analysis fibrate use was an independent predictor of cardiovascular events and all-cause mortality. As only 12.4% of our 105 patients took fibrates and we had no follow-up data on medication use, this finding requires cautious and critical interpretation. Although fibrates can increase creatinine, the safety of their use above GFR 30 ml/min was confirmed by the huge, randomized FIELD study [35] .
Regarding to the studied serum markers, previously we found that Ang-2 increases with advanced CKD [12] . In line with this observation, in our current cohort Ang-2 was also elevated in more advanced CKD, although in multivariate analysis eGFR failed to remain an independent determinant of Ang-2. Whether the significant association between phosphorus and Ang-2 is only the consequence of decreased kidney function, or it represents yet another facet of mineral bone disease, remains to be investigated. Another independent determinant of Ang-2 level was CRP, which was also found to be associated with Ang-2 in coronary heart disease patients [36] . Ang-2, via the loss of Tie-2 signaling, destabilizes the endothelium and facilitates inflammatory response to cytokines [37] , and this may be an explanation for this association. Finally, Ang-2 was inversely related to serum cholesterol level. The explanation for this observation is not clear so far, but this finding is in line with our previous study, in which the same inverse relationship was found in more advanced CKD [12] .
Although in univariate analysis Ang-2 was a predictor of both outcomes, in multivariate analysis Ang-2 failed to remain an independent risk factor. This is in contrast with our previous study, in which Ang-2 was found to predict mortality in CKD patients independent of other risk factors [8] . Perhaps the less severe renal failure among our current population may explain for these contradictory results.
Regarding to ADMA and SDMA, the other two biochemical markers measured in our study, we found their elevated levels in those with more advanced CKD, which is in line with the literature data [9, 38] . Although ADMA was found to be the predictor of mortality or cardiovascular events in ESRD previously, as well as in patients with advanced CKD [9, 39, 40] , in our current study neither ADMA nor SDMA predicted the outcomes. We assume that differences in the patient population or the used medications may have led to this conflicting finding. Almost all our patients had hypertension (98%) and most took RAAS (renin-angiotensin-aldosterone system) inhibitors (88.6%). Previously RAAS inhibitors were found to reduce serum ADMA levels and that the use of RAAS inhibitors was an independent predictor of arginine/ADMA ratio [41, 42] . Although no medication was an independent predictor of ADMA in our study, the use of RAAS inhibitors had the highest point estimate among medications (b: À0.130, P ¼ 0.138). Moreover, the use of RAAS inhibitors was an independent negative predictor of SDMA. The ratio of patients who took RAAS inhibitors was much lower in the study of Hov et al. [40, 41] (74%) and Lu et al. [9] (34%). Moreover, our patients were younger compared with those of Lu et al. [9] . Age was an independent predictor of ADMA level in our study and in the study of Hov et al. [41] as well. Furthermore, diabetes was more frequent (47%) among our patients compared with the study of Hov et al. [40, 41] . Significantly, in the large population-based study of Böger et al. [43] , in patients with diabetes ADMA failed to predict mortality. The same authors hypothesized that this phenomenon may be explained by the observed uncoupling of endothelial NO synthase (eNOS) in diabetes [44] . The activity of uncoupled eNOS can lead to excessive superoxide production that can have detrimental effects directly or by reacting with vascular NO to form the highly reactive peroxynitrite. Under this condition, the inhibition of the uncoupled eNOS by ADMA or SDMA can have an unexpected beneficial effect and might modify the survival of patients [44] . This hypothesis however has never been tested in diabetic CKD patients.
A limitation of our study is the relatively low number of patients involved; however, this is counterbalanced by the long follow-up period and by the use of multiple failure time analysis both of which likely decreased the chance of a beta-error. Given the relatively low number of participants and outcome events, we decided to use a stepwise elimination of potential covariates (even those that may be physiologically connected), in line with the hypothesis generating purpose of our study. According to a posthoc power analysis, given the mean values and standard deviation observed for lnPORH in participants with and without an outcome (5.83, 6.38, 1.21, respectively), an alpha of 0.05, we had a 69% power to detect the observed difference. Our sophisticated analysis however probably provided somewhat larger power than the calculated as it took into account time to the event and also multiple events within participants. Another limitation comes from the convenience sampling with consecutive enrollment of patients in the two tertiary care nephrology clinics, and therefore selection bias that may limit generalizability (i.e. high baseline cardiovascular disease risk burden of our patients) cannot be ruled out.
In conclusions, among the studied LDF and biochemical microvascular parameters, only PORH HA predicted cardiovascular events and cardiovascular mortality, although even PORH HA lost its statistical significance when all-cause mortality and cardiovascular events were considered as outcome. Although the robustness of traditional, Framingham risk factors seems to outweigh the predictive role of microvascular biomarkers on all-cause mortality and cardiovascular events, the latter seems to be an additional marker to improve cardiovascular risk assessment in CKD. Our study confirms the role of age, diabetes or brachial pulse pressure on clinical outcome prediction in CKD patients that may further be improved by the evaluation of this simple laser-Doppler parameter.
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Reviewer 2
In this prospective cross-sectional study the authors analyzed the relation between laser Doppler flowmetry (LDF) parameters (i.e. postocclusion reactive hyperemia area), conventional risk factors and markers of microvascular dysfunction in patients with chronic renal failure not on dialysis. The prognostic value of LDF and biochemical markers to predict cardiovascular events and cardiovascular and all-cause mortality was evaluated. A limitation of the analysis is the relatively small number of patients included, however this is partially compensated by a long-follow-up period and multiple failure time analysis. While in this analysis the predictive value of biomarkers of microvascular dysfunction seems to be outweighed by classical Framingham risk factors, postocclusion reactive hyperemia area seems to improve the prediction of cardiovascular risk in patients with chronic kidney disease. However, the clinical significance of LDF to predict cardiovascular risk remains to be confirmed by further studies.
